Preventing pneumonia after brain hemorrhage with extra mouth care and preventive antibiotics
Official title: Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia
Run by Beijing Tiantan Hospital · NCT07311343 · Data updated 2026-11-12
This will test whether enhanced oral hygiene combined with preventive antibiotics can help adults who recently had a spontaneous intracerebral hemorrhage avoid pneumonia.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 440 (estimated) |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 7, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | October 31, 2027 |
| Registry record updated | February 12, 2026 |
| Trial ID | NCT07311343 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–80 years with spontaneous supratentorial intracerebral hemorrhage within 72 hours, hematoma volume <30 ml, GCS ≥9, ICH-APS ≥8, and able to give informed consent are ideal candidates.
✕Probably not a fit
Patients with secondary causes of hemorrhage (for example aneurysm, tumor, venous thrombosis), signs of brain herniation, obvious pneumonia at enrollment, or other major exclusion criteria are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, controlled, open-label trial with blinded endpoint assessment comparing enhanced oral hygiene plus prophylactic antibiotics to usual care in adults with recent spontaneous supratentorial intracerebral hemorrhage. Eligible patients are enrolled within 72 hours of symptom onset, have hematoma volume under 30 ml and a higher risk score for stroke-associated pneumonia. The trial measures whether the combined intervention reduces the incidence of post-hemorrhage pneumonia, monitors safety outcomes, and analyzes health-economic effects. Treatment is delivered in-hospital with planned follow-up to capture infections, adverse events, and resource use.
Why it matters
Potential benefit: If successful, this approach could reduce post-ICH pneumonia rates, shorten hospital stays, and improve recovery for patients.
How similar studies have gone: Similar enhanced oral care programs and selective antibiotic approaches have reduced pneumonia in some stroke and ICU populations, but combining enhanced oral hygiene with routine prophylactic antibiotics specifically after intracerebral hemorrhage is less well established and prior results have been mixed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Age 18-80 years old;
2. Spontaneous intracerebral hemorrhage;
3. Supratentorial intracerebral hemorrhage (ICH);
4. Hematoma volume \< 30 ml (calculated by ABC/2 method);
5. Glasgow Coma Scale score ≥ 9 at randomization;
6. Time from onset to randomization ≤ 72 hours;
7. Spontaneous intracerebral hemorrhage-associated pneumonia score (ICH-APS) ≥ 8;
8. Informed consent from the patient and/or their family.
Exclusion Criteria:
1. Secondary intracerebral hemorrhage, such as that resulting from cerebral aneurysms, cerebral arteriovenous malformations, brain tumors, cerebral venous system thrombosis, antithrombotic therapy (antiplatelet, anticoagulant therapy, etc.), hemorrhagic transformation after cerebral infarction, hematological diseases, etc.
2. The patient's clinical symptoms and signs suggest signs of brain herniation, such as progressive decline in consciousness level, weakened or absent pupillary light reflex.
3. Obvious signs of pneumonia already exist, such as fever, persistent cough or yellow purulent sputum, and imaging examinations (chest X-ray or chest CT) suggest signs of pneumonia; two consecutive measurements of body temperature ≥ 37.5℃, or one measurement of body temperature ≥ 38.0℃.
4. A history of severe cardiovascular disease, meeting any of the following: 1) Heart failure (New York Heart Association functional class ≥ III); 2) Unstable angina within 3 months; 3) Any supraventricular or ventricular arrhythmia requiring treatment; 4) Prolonged QTc interval considered clinically significant by the investigator (reference range: \> 450ms for men, \> 470ms for women) (Note: QTc interval must be calculated according to Fridericia's formula); 5) Complete atrioventricular block and left or right bundle branch block requiring treatment; 6) Acute myocardial infarction or interventional treatment within 1 month; high-risk patients with chronic arrhythmia, such as sick sinus syndrome, second or third-degree atrioventricular block, bradycardia-related syncope without pacemaker installation, etc.
5. Diagnosed with severe active liver disease, such as acute hepatitis, chronic active hepatitis, liver cirrhosis, etc.; or ALT or AST \> 3 times the upper limit of normal.
6. Severe renal insufficiency: such as patients undergoing dialysis, or diagnosed with severe active kidney disease, etc., or creatinine clearance rate \< 50 mL/min.
7. Other severe diseases that lead to an expected lifespan of less than 1 year.
8. Patients scheduled for surgical intervention before the first administration, including but not limited to hematoma evacuation (including minimally invasive and conventional surgery), decompressive craniectomy, hematoma aspiration, and external ventricular drainage.
9. Patients unable to understand the research procedures and/or complete follow-up due to mental illness, cognitive impairment, emotional disorders, etc.
10. Pregnant or lactating women.
11. Participation in other clinical studies within 3 months or currently participating in other clinical studies.
12. Known allergy to cephalosporins, penicillins, or chlorhexidine compound mouthwash.
\-
Where it's running
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Junping Guo — Beijing Tiantan Hospital
- Study coordinator: Xue Sun
- Email: sunxue1110@163.com
- Phone: 86+13521769614
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
A large biobank for acute and emergency medicine
This study is collecting health information and samples from patients with sudden illnesses in the Emergency Department to see if it can help improve treatments and predict how patients will do.
-
Understanding how drugs work in children
This study is trying to find the best and safest doses of certain medications for children and young adults under 21 who are being treated for conditions like COVID-19 and pulmonary arterial hypertension.
-
Respiratory Physiotherapy in Critically Ill Pneumonia Patients
This study tests whether a structured breathing and chest therapy program can change inflammatory biomarkers in adults with pneumonia in the ICU compared to usual care.
-
AI-powered CT help to guide pneumonia care
A multicenter trial tests whether using a chest CT–based AI report to guide care reduces death or need for new organ support in adults with pneumonia.
-
Wintergreen oil inhalation for shortness of breath in pneumonia patients
Hospitals will test whether inhaling wintergreen essential oil helps relieve dyspnea in adults with pneumonia.
-
Simplified Tranexamic Acid Regimen for Trauma with Hemorrhage
This trial tests a simplified TXA dosing approach to see if it safely helps adults with major trauma and significant bleeding.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.